Mutation detection The denaturing high-performance liquid chromat

Mutation detection The denaturing high-performance liquid chromatography (DHPLC) was used to detect mutations in the exon 19 and 21 of EGFR tyrosine kinase domains as described previously [28]. Statistical analysis All data were analyzed using

SPSS (version 16.0). Chi-square and Fisher’s exact tests were used to assess the association between DNA methylation and EGFR genotypes. Multivariate analysis LEE011 was performed using Cox proportional hazard regression model. The Kaplan-Meier method was used to determine the overall survival and progression-free survival curves. P value less than 0.05 was considered statistically significant. Results Characteristics of

study patients Table 1 summarized the demographic characteristics of 155 study patients, among which 118 cases were adenocarcinoma and 37 cases were non- adenocarcinoma (29 squamous carcinoma, 5 large cell carcinoma, and 3 adeno- squamous carcinoma cases). 60 of all patients received EGFR-TKI as the first-line therapy, while the rest had EGFR-TKI as the second- or more-line treatment. Among those 95 patients who had EGFR-TKI as the second- or more-line treatment, 63 patients took platinum-based chemotherapy as the first-line treatment. The median follow-up time for all patients was 22.4 months (from 2.4 to 77.2 months). Table 1 Methylation and mutation profile of NSCLC Clinical characteristics (cases) Methylation (%) EGFR mutation MK-2206 cell line Oxymatrine (%)   SFRP1 SFRP2 SFRP5

DKK3 WIF1 APC CDH1 Any gene   Gender                   Male (74) 30 (40.5) 20 (27.0) 9 (12.2) 9 (12.2) 3 (4.1) 13 (17.6) 7 (9.5) 44 (59.5) 36 (48.6) Female (81) 31 (38.3) 20 (24.7) 14 (17.3) 13 (16.0) 3 (3.7) 18 (22.2) 8 (9.9) 48 (59.3) 49 (60.5) Age                   <65 (89) 33 (37.1) 21 (23.6) 10 (11.2) 12 (13.5) 3 (3.4) 16 (18.0) 7 (7.9) 48 (53.9) 56 (62.9)* ≥65 (66) 28 (42.4) 19 (28.8) 13 (19.7) 10 (15.2) 3 (4.5) 15 (22.7) 8 (12.1) 44 (66.7) 29 (43.9) Smoking                   Never (93) 35 (37.6) 24 (25.8) 14 (15.1) 15 (16.1) 2 (2.2) 21 (22.6) 8 (8.6) 58 (62.4) 57 (61.3)* Smokers (62) 26 (41.9) 16 (25.8) 9 (14.5) 7 (11.3) 4 (6.5) 10 (16.1) 7 (11.3) 34 (54.8) 28 (45.2) Histology                   Adenocarcinoma (118) 46 (38.9) 30 (25.4) 16 (13.6) 16 (13.6) 4 (3.4) 21 (17.8) 14 (11.9) 72 (61.0) 65 (55.1) Non-adenocarcinoma (37) 15 (40.5) 10 (27.0) 7 (18.9) 6 (16.2) 2 (5.4) 7 (18.9) 1 (2.7) 20 (54.1) 20 (54.1) Total 61 (39.4) 40 (25.8) 23 (14.8) 22 (14.2) 6 (38.7) 31 (20%) 15 (9.7%) 92 (59.4%) 85 (54.8%) *The frequency of this group is significantly higher than their counterparts.

Comments are closed.